Slides From Hot Topics in NASH: Real-World Practice Implications of NASH Trial Designs

Expert faculty explain how to interpret endpoints used in NASH studies so you can evaluate emerging treatments.

Kenneth Cusi, MD, FACP, FACE
Program Director
Stephen A. Harrison, MD, COL (Ret.), FAASLD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.61 MB
Released: March 26, 2019

Acknowledgements

Provided by the American Gastroenterological Association

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.

Juan Pablo Frias, MD, FACE Philip N. Newsome, PhD, FRCPE Released: January 28, 2020

Hear CCO faculty Rita Basu, MD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests

Rita Basu, MD Released: January 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue